PP.35.13

Abstract

Objective: To prove that prevention of increased platelet aggregation as a thrombosis risk factor is highly important prophylactic action. Design and method: 36 pts (20 m + 16 f, age 55,4 ± 5,6 ys) with moderate arterial hypertension and diabetes mellitus were examined. Platelet aggregation was studied by the Born G method at Thromlite aggregometer with ADP inductors in concentration of 2,0 • 10 6 M from Sigma, ristocetin in concentration of 0.8 mg / ml from Renamo. All pts were divided into 2 compatible randomized groups: the main (18 pts) and the control one (18 pts). Basic antihypertensive therapy was prescribed for the control group, whereas pts from the main group also received atorvastatin 10 mg per day. The treatment course lasted 8 weeks. Results: No differences were observed between groups in clinical and biochemical parameters (p > 0.05). Baseline platelet aggregation in the main group were ADP 32,1 ± 5,3% and ristocetin 29,9 ± 4,2% versus 43,9 ± 3,1% and 40,2 ± 1,5% of the control group (p < 0.05). Atorvastatin treatment resulted in that both ADP - and ristocetin - induced platelet aggregation were significantly decreased in the main group (p < 0.05). Platelet aggregation decreased under the influence of ADP (p < 0.05), but not ristocetin (p > 0.05) in the control group. Conclusions: The use of atorvastatin in patients with arterial hypertension and diabetes reduced platelet aggregation. In addition to lipid-lowering activity atorvastatin has antiaggregation effect that can be recommended as a prevention method of thrombotic complications.